JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Overweight to Neutral and lowers the price target from $22 to $15.
Trip.com Group Q3 Adj. EPS $0.22 Beats $0.17 Estimate, Sales $969.00M Beat $934.38M Estimate
Trip.com Group (NASDAQ:TCOM) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.17 by 29.41 percent. This is a 69.23 percent increase over earnings of $0.13 per share from the
